Can you provide the last earnings date for VERONA PHARMA PLC - ADR?
VERONA PHARMA PLC - ADR (VRNA) last reported earnings on 8/6/2025.
VERONA PHARMA PLC - ADR (VRNA) Earnings History & Surprises
NASDAQ:VRNA • US9250501064
Current stock price
106.91 USD
+0.12 (+0.11%)
At close:
106.94 USD
+0.03 (+0.03%)
After Hours:
VRNA Earnings overview
Past quarterly earnings results for VERONA PHARMA PLC - ADR (VRNA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Nov 3, 2025
- Period
- Q3 / 2025
- EPS Estimate
- $0.27
- Revenue Estimate
- 123.03M
Last Reported
Most Recent- Release Date
- Aug 6, 2025
- Period
- Q2 / 2025
- EPS Reported
- $0.13
- EPS Surprise
- 154.90%
- Revenue Surprise
- 9.73%
Beat Rate
Last 8 Quarters 19%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | 0.13 | 0.05 | 154.90% | 114.77% | 103.138M | 93.991M | 9.73% | - |
| Q1 2025 | -0.16 | -0.15 | -4.58% | 50.00% | 76.256M | 54.437M | 40.08% | - |
| Q4 2024 | -0.40 | -0.30 | -34.07% | -122.22% | 36.655M | 33.712M | 8.73% | - |
| Q3 2024 | -0.56 | -0.51 | -9.80% | -211.11% | 5.624M | 2.055M | 173.67% | - |
| Q2 2024 | -0.88 | -0.30 | -192.46% | -1,000.00% | - | - | ||
| Q1 2024 | -0.32 | -0.17 | -91.30% | -33.33% | - | - | ||
| Q4 2023 | -0.18 | -0.27 | 32.13% | -12.50% | - | -100.00% | ||
| Q3 2023 | -0.18 | -0.29 | 36.97% | 21.74% | - | - | ||
| Q2 2023 | -0.08 | -0.30 | 73.19% | 75.00% | - | - | ||
| Q1 2023 | -0.24 | -0.19 | -23.84% | 40.00% | - | - | ||
| Q4 2022 | -0.16 | -0.10 | -53.04% | 60.00% | 460K | 3.643M | -87.37% | - |
| Q3 2022 | -0.23 | -0.17 | -37.49% | -243.75% | 3.643M | -100.00% | -100.00% | |
| Q2 2022 | -0.32 | -0.39 | 16.89% | 13.51% | - | - | ||
| Q1 2022 | -0.40 | -0.45 | 10.87% | -11.11% | - | - | ||
| Q4 2021 | -0.40 | -0.49 | 19.14% | - | - | - | ||
| Q3 2021 | 0.16 | -0.37 | 143.57% | 134.78% | 40M | 4.25M | 841.18% | - |
| Q2 2021 | -0.37 | -0.45 | 17.18% | 43.94% | - | - | ||
| Q1 2021 | -0.36 | -0.48 | 25.51% | 62.11% | - | - | ||
| Q4 2020 | -0.40 | -0.36 | -12.04% | - | - | - | ||
| Q3 2020 | -0.46 | -0.22 | -108.14% | - | - | - | ||
| Q2 2020 | -0.66 | -0.48 | -36.70% | - | - | - | ||
| Q1 2020 | -0.95 | -0.67 | -42.56% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
26.61%
Max EPS beat (4)
154.90%
Min EPS beat (4)
-34.07%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
58.05%
Max Revenue beat (4)
173.67%
Min Revenue beat (4)
8.73%
Analysis
In the last 4 quarters, VRNA has beaten EPS estimates in 1 out of 4 releases
VRNA has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, VRNA has beaten the EPS estimates by 26.6% on average.
In the last 4 quarters, VRNA has beaten the revenue estimates by 58.1% on average.
Related analysis
VERONA PHARMA PLC - ADR / VRNA Earnings FAQ
Did VERONA PHARMA PLC - ADR (VRNA) beat earnings estimates last quarter?
VERONA PHARMA PLC - ADR (VRNA) beat EPS estimates and beat revenue estimates in the most recent quarter.
How often does VERONA PHARMA PLC - ADR (VRNA) beat earnings estimates?
In the last 4 quarters, VERONA PHARMA PLC - ADR (VRNA) has beaten EPS estimates in 1 out of 4 releases.